AB 105
Alternative Names: AB-105Latest Information Update: 27 Feb 2024
At a glance
- Originator Applied Biology
- Developer Safety Shot
- Class Skin disorder therapies; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Alopecia
Most Recent Events
- 20 Feb 2019 Applied Biology plans a phase III trial for Alopecia (Prevention) (Topical) in Q1 2019 (Applied Biology pipeline, February 2019)
- 01 Feb 2019 Clinical trials in Alopecia (Prevention) (Topical) before February 2019 (Applied Biology pipeline, February 2019)